Borrelia Burgdorferi

The dosage of Borrelia burgdorferi allergenic extract is highly individualized and depends entirely on the purpose of administration (e.g., skin testing vs. laboratory diagnostic use). For diagnostic skin testing, the standard dose is typically 0.02 mL to 0.1 mL of a specific dilution (e.g., 1:100 or 1:1000 w/v) administered intradermally. If used as part of an immunotherapy research protocol, the dose may be escalated gradually starting from a very low concentration to build immune tolerance, though this is not a common clinical practice for this specific agent.

Borrelia burgdorferi extracts are not routinely approved for pediatric use in the context of allergenic immunotherapy. However, they are used in diagnostic laboratory testing for children of all ages. If a skin test is required for a pediatric patient, the healthcare provider will calculate the dose based on the child's age, weight, and the specific diagnostic requirement, often using smaller volumes (e.g., 0.01 mL to 0.05 mL) to minimize the risk of a systemic reaction.

Renal Impairment

No specific dosage adjustments are typically required for patients with renal (kidney) impairment, as the systemic absorption of the extract is minimal. However, clinicians should monitor for delayed clearance of the inflammatory response in patients with end-stage renal disease.

Hepatic Impairment

Since Borrelia burgdorferi extracts are not metabolized by the liver, no dosage adjustments are necessary for patients with hepatic (liver) impairment.

Elderly Patients

Geriatric patients may have a diminished skin reaction (reduced wheal and flare) due to age-related changes in skin elasticity and immune responsiveness. Healthcare providers may need to adjust the concentration of the extract to ensure an accurate diagnostic result.

Borrelia burgdorferi extracts are strictly for professional use and are never self-administered by the patient.

• Administration: The extract is usually injected just below the surface of the skin (intradermal) on the inner forearm or the back.
• Preparation: The site must be cleaned with an antiseptic (like alcohol) before injection.
• Observation: After administration, the patient must remain in the healthcare facility for at least 30 minutes to be monitored for signs of a severe allergic reaction (anaphylaxis).
• Storage: The extract must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). It should never be frozen, as freezing can denature the proteins and render the extract ineffective.

If a scheduled diagnostic test or immunotherapy session is missed, it should be rescheduled as soon as possible. Because these are not daily medications, a missed dose does not carry the same risk as missing a chronic medication, but it may delay diagnosis or the progression of an immunological protocol.

An overdose of Borrelia burgdorferi extract occurs if too high a concentration or too large a volume is injected.

• Signs of Overdose: Excessive swelling at the injection site, widespread hives (urticaria), difficulty breathing, or a drop in blood pressure.
• Emergency Measures: If an overdose is suspected, immediate administration of epinephrine (adrenaline) may be required. Healthcare providers will also use antihistamines and corticosteroids to manage the inflammatory response.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most frequent side effects associated with the administration of Borrelia burgdorferi extracts are localized to the site of injection. These typically appear within minutes to hours and may include:

• Erythema (Redness): A red patch around the injection site that may feel warm to the touch.
• Pruritus (Itching): Intense itching at the site of administration.
• Induration (Swelling): A firm, raised bump (wheal) that typically resolves within 24 to 48 hours.
• Tenderness: Mild pain or soreness when the area is touched.

Some patients may experience more widespread but non-life-threatening reactions, such as:

• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit if the forearm was used).
• Malaise: A general feeling of discomfort or fatigue.
• Low-grade Fever: A slight elevation in body temperature as the immune system responds to the antigens.
• Myalgia (Muscle Pain): Generalized body aches similar to a mild flu.

Rarely, the administration of bacterial extracts can trigger more significant systemic responses:

• Urticaria (Hives): Itchy red welts appearing on parts of the body far from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Syncope (Fainting): Often a vasovagal response to the injection itself rather than the extract.

> Warning: Stop taking Borrelia Burgdorferi and call your doctor immediately if you experience any of these.

• Anaphylaxis: This is a life-threatening allergic reaction characterized by a rapid pulse, difficulty breathing, swelling of the throat, and a sharp drop in blood pressure. It requires immediate treatment with epinephrine.
• Jarisch-Herxheimer Reaction: While more common during antibiotic treatment for Lyme disease, exposure to high levels of Borrelia antigens can theoretically trigger this reaction, characterized by high fever, chills, and worsening of inflammatory symptoms.
• Severe Bronchospasm: Sudden constriction of the airways causing wheezing and extreme shortness of breath.
• Seizures: Extremely rare, but possible in the event of a severe systemic inflammatory response.

Because Borrelia burgdorferi extracts are typically used for short-term diagnostic purposes, long-term side effects are rare. However, repeated exposure in an immunotherapy context could potentially lead to:

• Persistent Granuloma: A small, firm knot of tissue at the injection site that may last for weeks or months.
• Chronic Sensitization: In rare cases, the patient may become more sensitive to the antigen over time, increasing the risk of future reactions.

No FDA black box warnings are currently issued for Borrelia burgdorferi allergenic extracts. However, all allergenic extracts carry a general warning regarding the risk of severe systemic reactions, including anaphylaxis, and must only be administered by clinicians prepared to manage such emergencies.

Report any unusual symptoms to your healthcare provider.

Borrelia burgdorferi extracts must be used with extreme caution in patients with a history of severe allergies or asthma. Because these extracts are designed to provoke an immune response, there is an inherent risk that the response may become systemic and life-threatening. Patients should always inform their healthcare provider of any previous reactions to tick bites or Lyme disease diagnostic tests.

No FDA black box warnings for Borrelia Burgdorferi. However, the FDA requires that all potent allergenic extracts be administered in a facility equipped with emergency resuscitative equipment, including oxygen, IV fluids, and epinephrine.

• Allergic Reactions / Anaphylaxis Risk: The primary risk is a Type I hypersensitivity reaction. Patients with unstable asthma are at a significantly higher risk for severe bronchospasm following administration.
• Organ-Specific Risks: There is no evidence of direct hepatotoxicity or nephrotoxicity from the small doses used in diagnostic extracts. However, patients with pre-existing autoimmune conditions (like Rheumatoid Arthritis) should be monitored, as the immune stimulation could theoretically trigger a flare of their condition.
• Cardiotoxicity: In patients with pre-existing Lyme carditis (heart inflammation caused by the bacteria), exposure to extracts should be handled with extreme care to avoid exacerbating arrhythmias or conduction blocks.

• Observation Period: Patients must be monitored for at least 30 to 60 minutes post-injection.
• Skin Site Assessment: The injection site should be measured and documented at 15-20 minutes (early phase) and sometimes at 24-48 hours (late phase).
• Vital Signs: In high-risk patients, blood pressure and heart rate should be checked before and after administration.

Borrelia burgdorferi extracts do not typically cause sedation. However, if a patient experiences a vasovagal reaction (fainting) or a systemic allergic reaction, they should not drive until they are fully recovered and cleared by a medical professional.

There is no direct pharmacological interaction between alcohol and Borrelia burgdorferi extracts. However, alcohol can cause vasodilation (widening of blood vessels), which might increase the rate of absorption of the extract and potentially worsen a localized or systemic allergic reaction.

As this is usually a one-time or infrequent diagnostic agent, there are no tapering requirements. If a patient is undergoing a series of tests and experiences a moderate-to-severe reaction, the healthcare provider will likely discontinue the use of the extract immediately.

> Important: Discuss all your medical conditions with your healthcare provider before starting Borrelia Burgdorferi.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are contraindicated in patients receiving potent allergenic extracts. If a patient on a beta-blocker has an anaphylactic reaction to the Borrelia extract, the beta-blocker can interfere with the effectiveness of epinephrine, making the reaction much harder to treat and potentially fatal.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of systemic reactions or worsen the severity of hypotension (low blood pressure) during an allergic event.
• Immunosuppressants (e.g., Cyclosporine, Methotrexate): These drugs may suppress the immune system's ability to react to the Borrelia antigen, leading to a false-negative result in diagnostic tests.

• Systemic Corticosteroids (e.g., Prednisone): Long-term use of steroids can dampen the skin's inflammatory response, potentially masking a positive diagnostic reaction.
• Antihistamines (e.g., Cetirizine, Diphenhydramine): These MUST be discontinued several days before skin testing, as they directly block the histamine response that creates the 'wheal and flare' reaction.

There are no known direct food interactions with Borrelia burgdorferi extracts. However, patients should avoid consuming large amounts of caffeine before a diagnostic test, as it may increase heart rate and make it difficult to monitor for allergic tachycardia.

• St. John’s Wort: While primarily known for CYP interactions, its effect on systemic inflammation is poorly understood; patients should disclose its use.
• High-dose Vitamin C: Some studies suggest very high doses of Vitamin C may have a mild antihistamine effect, which could theoretically interfere with skin test results.

• Syphilis Serology: Because Borrelia burgdorferi and Treponema pallidum (the cause of syphilis) are both spirochetes, there can be cross-reactivity. Exposure to Borrelia antigens might cause a false-positive result on certain syphilis screening tests.

For each major interaction, the mechanism usually involves either the pharmacodynamic blocking of the body's emergency response (beta-blockers) or the suppression of the very immune response the extract is trying to measure (steroids/antihistamines).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Previous Anaphylaxis to Borrelia Antigens: Any patient who has had a life-threatening reaction to a Lyme disease vaccine or previous diagnostic extract must never receive it again.
• Acute Lyme Disease Infection: The extract should not be used for skin testing during the acute phase of an active infection (e.g., when erythema migrans is present), as the immune system is already hyper-reactive and the risk of a systemic reaction is elevated.
• Severe Uncontrolled Asthma: Patients with a Forced Expiratory Volume (FEV1) consistently below 70% of predicted values are at an unacceptable risk for fatal bronchospasm.

• Pregnancy: While not strictly forbidden, the risk of a systemic reaction (which could cause fetal distress) usually outweighs the benefit of diagnostic skin testing during pregnancy.
• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or multiple sclerosis (MS) may experience a flare of their condition due to the immunostimulatory nature of the extract.
• Beta-Blocker Therapy: As noted in the interactions section, this is a major safety concern that requires a careful risk-benefit analysis.

Patients who are allergic to other members of the Borrelia genus (such as Borrelia mayonii or Borrelia afzelii) are highly likely to react to Borrelia burgdorferi extracts due to the similarity of their surface proteins.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Borrelia Burgdorferi.

Borrelia burgdorferi extracts are generally classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. The primary concern is not the direct effect of the bacterial proteins on the fetus, but the potential for the mother to experience anaphylaxis, which can lead to maternal hypoxia (lack of oxygen) and subsequent fetal brain injury or death. Diagnostic testing using these extracts should be deferred until after delivery unless the information is critical for managing a life-threatening condition.

It is unknown whether Borrelia burgdorferi antigenic fragments are excreted in human milk. However, because the proteins are large and the dose is very small, it is unlikely that significant amounts would reach the infant through breastfeeding. The risk-benefit ratio should be discussed with a healthcare provider, particularly if the nursing infant has known allergies.

Safety and effectiveness of Borrelia burgdorferi as an allergenic extract for immunotherapy have not been established in children under the age of 18. In diagnostic laboratory settings, it is used safely across all pediatric age groups, but skin testing in small children is generally avoided due to the difficulty of interpreting results and the risk of systemic distress.

Clinical studies have shown that elderly patients (over 65) may have a reduced cutaneous (skin) response to allergenic extracts. This can lead to false-negative skin tests. Additionally, elderly patients are more likely to be on medications like beta-blockers or ACE inhibitors, which increase the risk of complications if a reaction occurs. Healthcare providers should perform a thorough cardiovascular assessment before administration.

In patients with chronic kidney disease (CKD), the immune system may be uremic (affected by toxins in the blood), which can dampen the delayed-type hypersensitivity response. No specific dose adjustment is required, but the clinician should be aware that the test's sensitivity may be reduced.

There are no specific precautions for patients with liver disease, as the metabolism of these biological proteins does not rely on hepatic function. However, patients with advanced cirrhosis may have coagulopathies (bleeding disorders) that increase the risk of bruising at the injection site.

> Important: Special populations require individualized medical assessment.

Borrelia burgdorferi extract acts as a complex biological antigen. The primary molecular targets are the Toll-like Receptor 2 (TLR2) and CD14 molecules on the surface of macrophages and dendritic cells. When the extract's lipoproteins (such as OspA) bind to these receptors, they trigger the NF-κB signaling pathway. This leads to the production of pro-inflammatory cytokines and the upregulation of major histocompatibility complex (MHC) class II molecules, which present the Borrelia peptides to T-cells. This molecular recognition is the basis for the diagnostic inflammatory response.

The pharmacodynamic effect is measured by the diameter of the skin reaction (wheal and flare). The onset of the early-phase reaction (IgE-mediated) occurs within 15-30 minutes. A late-phase reaction (cell-mediated) may occur 6-24 hours later. The duration of the immunological 'memory' triggered by these antigens can last for years, which is why diagnostic tests can remain positive long after an infection has cleared.

| Parameter | Value |

|---|---|

| Bioavailability | Localized (Minimal Systemic) |

| Protein Binding | High (to local tissue proteins) |

| Half-life | 4 - 12 hours (at injection site) |

| Tmax | 15 - 30 minutes (local reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Lymphatic clearance |

• Molecular Formula: N/A (Complex biological mixture)
• Molecular Weight: Varies (OspA is approx. 31 kDa; OspC is approx. 22 kDa)
• Solubility: Soluble in aqueous buffered saline solutions.
• Description: A sterile, non-pyrogenic solution containing the extracted proteins, lipids, and carbohydrates from the Borrelia burgdorferi spirochete.

Borrelia burgdorferi is classified as a Standardized Pollen Allergenic Extract [EPC] (in the context of broad regulatory categories for allergenic products) and a Diagnostic Antigen. It is related to other bacterial extracts and the historical OspA vaccine.